Evidence map›Paper›PMID 24741091›Full record

ArticleJournal of virology2014

Analysis of Lujo virus cell entry using pseudotype vesicular stomatitis virus.

Hideki Tani, Koichiro Iha, Masayuki Shimojima, Shuetsu Fukushi, Satoshi Taniguchi, Tomoki Yoshikawa, Yoshihiro Kawaoka, Naoe Nakasone, Haruaki Ninomiya, Masayuki Saijo and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Strategies of rational and structure-driven vaccine design for Arenaviruses.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2024
    Review
  3. Article
  4. Entry inhibitors as arenavirus antivirals.Frontiers in microbiology · 2024
    Review
  5. Article
  6. Pseudotyped Viruses for Mammarenavirus.Advances in experimental medicine and biology · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Antiviral activity of cationic amphiphilic drugs.Expert review of anti-infective therapy · 2017
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hideki TaniSpecial Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases, University of Tokyo, Tokyo, Japan.
Koichiro IhaSpecial Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases, University of Tokyo, Tokyo, Japan Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan.
Masayuki ShimojimaSpecial Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases, University of Tokyo, Tokyo, Japan.
Shuetsu FukushiSpecial Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases, University of Tokyo, Tokyo, Japan.
Satoshi TaniguchiSpecial Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases, University of Tokyo, Tokyo, Japan Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan.
Tomoki YoshikawaSpecial Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases, University of Tokyo, Tokyo, Japan.
Yoshihiro KawaokaDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Naoe NakasoneDepartment of Biomedical Regulation, School of Health Sciences, Tottori University Faculty of Medicine, Tokyo, Japan.
Haruaki NinomiyaDepartment of Biomedical Regulation, School of Health Sciences, Tottori University Faculty of Medicine, Tokyo, Japan.
Masayuki SaijoSpecial Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases, University of Tokyo, Tokyo, Japan.
Shigeru MorikawaDepartment of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan morikawa@nih.go.jp.
The University of Tokyo · JPNational Institute of Infectious Diseases · JPTottori University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledSeveral arenaviruses are known to cause viral hemorrhagic fever (VHF) in sub-Saharan Africa and South America, where VHF is a major public health and medical concern. The biosafety level 4 categorization of these arenaviruses restricts their use and has impeded biological studies, including therapeutic drug and/or vaccine development. Due to difficulties associated with handling live viruses, pseudotype viruses, which transiently bear arenavirus envelope proteins based on vesicular stomatitis virus (VSV) or retrovirus, have been developed as surrogate virus systems. Here, we report the development of a pseudotype VSV bearing each envelope protein of various species of arenaviruses (AREpv), including the newly identified Lujo virus (LUJV) and Chapare virus. Pseudotype arenaviruses generated in 293T cells exhibited high infectivity in various mammalian cell lines. The infections by New World and Old World AREpv were dependent on their receptors (human transferrin receptor 1 [hTfR1] and α-dystroglycan [αDG], respectively). However, infection by pseudotype VSV bearing the LUJV envelope protein (LUJpv) occurred independently of hTfR1 and αDG, indicating that LUJpv utilizes an unidentified receptor. The pH-dependent endocytosis of AREpv was confirmed by the use of lysosomotropic agents. The fusion of cells expressing these envelope proteins, except for those expressing the LUJV envelope protein, was induced by transient treatment at low pH values. LUJpv infectivity was inhibited by U18666A, a cholesterol transport inhibitor. Furthermore, the infectivity of LUJpv was significantly decreased in the Niemann-Pick C1 (NPC1)-deficient cell line, suggesting the necessity for NPC1 activity for efficient LUJpv infection. IMPORTANCE: LUJV is a newly identified arenavirus associated with a VHF outbreak in southern Africa. Although cell entry for many arenaviruses has been studied, cell entry for LUJV has not been characterized. In this study, we found that LUJpv utilizes neither αDG nor hTfR1 as a receptor and found unique characteristics of LUJV glycoprotein in membrane fusion and cell entry. Proper exclusion of cholesterol or some kinds of lipids may play important roles in LUJpv cell entry.

Indexed as

Virus InternalizationAnimalsArenaviridae InfectionsCarrier ProteinsCholesterolFluorescent Antibody TechniqueHumansImmunoblottingIntracellular Signaling Peptides and ProteinsLujo virusMembrane GlycoproteinsNiemann-Pick C1 ProteinReceptors, Cell SurfaceSphingolipidsVesicular StomatitisVesicular stomatitis Indiana virusCarrier ProteinsCholesterolIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsNiemann-Pick C1 ProteinNPC1 protein, humanReceptors, Cell SurfaceSphingolipidsViral Envelope Proteins

Identifiers

PMID24741091
PMCPMC4054455
OpenAlexW1989427969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.